nContact, headquartered in North Carolina, USA, was founded to develop medical devices for the minimally-invasive treatment of heart arrhythmias, including atrial fibrillation (AF) and atrial flutter (AFL).

Our enabling product, the Numeris^® Coagulation System with VisiTrax^®, has CE Mark approval in Europe for the coagulation of cardiac tissue for the treatment of AF, and can be used in open chest, concomitant procedures as well as in closed chest, convergent procedures.

Utilizing the nContact coagulation system and an ablation catheter, the convergent procedure combines the best techniques of Cardiovascular Surgeons and Electrophysiologists to provide a truly minimally-invasive treatment solution for all AF patients in a single procedure.

For information about our US operations and ongoing US clinical trials, please visit http://www.ncontactsurgical.us/